Elevation oncology, the latest news was that a positive for elevation oncology

Here is the relevant news:1. Elevation Oncology's Stock Surge: Elevation Oncology's stock has seen a significant increase of 213% over the past week, with a one-year return on investment of 176%. This is due to the company's large hedge fund owners, who hold 29% of the business. The company's stock price may be vulnerable to their trading decisions.2. Global Oncology Cancer Drugs Market Growth: The global Oncology Cancer Drugs market is projected to surpass $289 billion by 2030, driven by the increasing number of Americans aged 65 and older and the focus on cancer research. This growth may benefit companies like Elevation Oncology that are involved in cancer treatments.3. HC Wainwright's Coverage of Elevation Oncology: HC Wainwright & Co. has initiated coverage of Elevation Oncology with a Buy recommendation, forecasting a 951.91% upside. The company's average one-year price target is $6.97, indicating a significant increase from its latest reported closing price of $0.66.